argenx SE (NASDAQ:ARGX) Receives Consensus Rating of “Moderate Buy” from Analysts

argenx SE (NASDAQ:ARGX) has earned an average recommendation of “Moderate Buy” from the twenty-three analysts that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, eighteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $615.50.

A number of research firms have recently issued reports on ARGX. Oppenheimer boosted their price target on shares of argenx from $560.00 to $646.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Piper Sandler upped their price objective on shares of argenx from $553.00 to $620.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Robert W. Baird lowered shares of argenx from an “outperform” rating to a “neutral” rating and upped their price objective for the company from $515.00 to $650.00 in a research note on Friday, November 1st. Finally, Wedbush upped their price objective on shares of argenx from $519.00 to $560.00 and gave the company an “outperform” rating in a research note on Friday, July 26th.

Institutional Trading of argenx

Several large investors have recently modified their holdings of the company. Profund Advisors LLC boosted its holdings in shares of argenx by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after buying an additional 28 shares during the period. Wealth Alliance boosted its holdings in argenx by 4.8% in the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after purchasing an additional 29 shares during the period. GAMMA Investing LLC boosted its holdings in argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares during the period. Toronto Dominion Bank boosted its holdings in argenx by 16.5% in the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after purchasing an additional 43 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its holdings in argenx by 3.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock valued at $737,000 after purchasing an additional 52 shares during the period. 60.32% of the stock is owned by institutional investors.

argenx Price Performance

ARGX stock opened at $596.00 on Friday. argenx has a 12 month low of $327.73 and a 12 month high of $611.22. The firm has a market cap of $35.64 billion, a PE ratio of -677.27 and a beta of 0.61. The firm has a 50 day simple moving average of $547.05 and a 200 day simple moving average of $474.44.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the previous year, the business earned ($1.25) earnings per share. As a group, sell-side analysts expect that argenx will post 2.2 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.